Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer

Clinical Cancer Research

Volumn 5, Issue 10 SUPPL., 1999, Pages

  Winthrop, Michelle D ^a   DeNardo, Sally J ^a,b   DeNardo, Gerald L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Molecular Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERIMMUNE GLOBULIN; MONOCLONAL ANTIBODY; MUCIN;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; BREAST CANCER; CANCER IMMUNOLOGY; CELL STRAIN MCF 7; CONFERENCE PAPER; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; BACTERIOPHAGES; BREAST NEOPLASMS; CA-15-3 ANTIGEN; DNA FINGERPRINTING; FEMALE; GENE LIBRARY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; TUMOR CELLS, CULTURED;

EID: 0032697611     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. DeNardo, S. J., Warhoe, K. A., O'Grady, L. F., Macey, D. J., Gobuty, A., Hellstrom, I., Hellstrom, K. E., Kroger, L. A., and DeNardo, G. L. Response to I-131 chimeric MoAb L6 radioimmunotherapy in patients with advanced metastatic breast cancer. J. Nucl. Med., 32: 922, 1991.
2. DeNardo, S. J., Kramer, E. L., O'Donnell, R. T., Richman, C. M., Salako, Q. A., Shen, S., Noz, M., Glenn, S. D., Ceriani, R. L., and DeNardo, G. L. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a Phase I clinical trial. J. Nucl. Med., 38: 1180-1185, 1997.
3. 90Y Mx-diethylenetriaminepentaacetic acid (DTPA)-BrE-3 and autologous hematopoietic stem cell support (AHSCS) for the treatment of advanced breast cancer: a Phase I trial. Cancer Res., 55 (Suppl.): 5921s-5924s, 1995.
4. Reilly, R. M., Sandhu, J., Alvarez-Diez, T. M., Gallinger, S., Kirsh, J., and Stern, H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet., 28: 126-142, 1995.
5. Chester, K. A., and Hawkins, R. E. Advances in antibody technology for targeted cancer therapy. Tumor Marker Update, 6: 187-195, 1994.
6. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., and Morgan, A. C., Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., 45: 879-885, 1985.
7. Kramer, E. L., DeNardo, S. J., Liebes, L., Kroger, L. A., Noz, M. E., Mizrachi, H., Salako, Q. A., Furmanski, P., Glenn, S. D., and DeNardo, G. L. Radioimmunolocalization of breast carcinoma using BrE-3 monoclonal antibody: Phase I study. J. Nucl. Med., 34: 1067-1074, 1993.
8. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res., 55 (Suppl.): 5916s-5920s, 1995.
9. Hu, S. Z., Raubitschek, A., Sherman, A., Williams, L. E., Wong, J. Y., Shively, J. E., and Wu, A. M. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain-Fv-Ch3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 56: 3055-3061, 1996.
10. Adams, G. P., Schier, R., McCall, A. M., Crawford, S. M., Wolff, E. J., Weiner, M., and Marks, J. D. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer, 77: 1405-1412, 1998.
11. Adams, G. P. Improving the tumor specificity and retention of antibody-based molecules. In Vivo, 12: 11-22, 1998.
12. Luiten, R. M., Coney, L. R., Warnaar, S. O., and Litvinov, S. V. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br. J. Cancer, 74: 735-744, 1996.
13. Froyen, G., and Billiau, A. Potential therapeutic use of antibodies directed towards the HuIFN-γ. Biotherapy, 10: 49-57, 1997.
14. Hoogenboom, H. R., Griffiths, A. D., Johnson, K. S., Chiswell, D. J., Hudson, P., and Winter, G. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res., 19: 4133-4137, 1991.
15. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. Making antibodies by phage display technology. Annu. Rev. Immunol, 12: 433-455, 1994.
16. McCafferty, J., Griffiths, A. D., Winter, G., and Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature (Lond.), 348: 552-554, 1990.
17. Johnson, K. S., and Chiswell, D. J. Human antibody engineering. Curr. Opin. Struct. Biol., 3: 564-571, 1993.
18. Pope, A. R., Embleton, M. J., and Mernaugh, R. Construction and use of antibody gene repertoires. In: McCafferty, H. R. Hoogenboom, and D. J. Chiswell (eds.), Antibody Engineering: A Practical Approach, pp. 1-39. New York: Oxford University Press, 1996.
19. Chester, K. A., Begent, R. H., Robson, L., Keep, P., Pedley, R. B., Boden, J. A., Boxer, G., Green, A., Winter, G., and Cochet, O. Phage libraries for generation of clinically useful antibodies. Lancet, 343: 455-456, 1994.
20. Winter, G., and Milstein, C. Man-made antibodies. Nature (Lond.), 349: 293-299, 1991.
21. Barratt-Boyes, S. M. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother., 43: 142-151, 1996.
22. Pemberton, L. F., Rughetti, A., Taylor-Papadimitriou, J., and Gendler, S. J. The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells. J. Biol. Chem., 271: 2332-2340, 1996.
23. Regimbald, L. H., Pilarski, L. M., Longenecker, B. M., Reddish, M. A., Zimmermann, G., and Hugh, J. C. The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res., 56: 4244-4249, 1996.
24. Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S., and Finn, O. J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res., 54: 2856-2860, 1994.
25. Fontenot, J. D., Tjandra, N., Bu, D., Ho, C., Montelaro, R. C., and Finn, O. J. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (MUC-1) protein core. Cancer Res., 53: 5386-5394, 1993.
26. Larocca, D., Peterson, J. A., Urrea, R., Kuniyoshi, J., Bistrain, A., Walkup, G., and Ceriani, R. L. Molecular cloning and expression of breast mucin-associated antigens. In: Breast Epithelial Antigens: Molecular Biology to Clinical Applications, pp. 35-54. New York: Plenum Press, 1991.
27. Carter, P., Ridgway, J., and Zhu, Z. Toward the production of bispecific antibody fragments for clinical applications. J. Hematother., 4: 463-470, 1995.
28. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222: 581-597, 1991.
29. Hoogenboom, H. R. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends. Biotechnol, 15: 62-70, 1997.
30. DeNardo, S. J., Kukis, D. L., Miers, L., Winthrop, M. D., Kroger, L. A., Salako, Q. A., Shen, S., Lamborn, K. R., Gumerlock, P. H., Meares, C. F., and DeNardo, G. L. Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J. Nucl. Med., 39: 842-849, 1998.
31. Gorga, J. C., Horejsi, V., Johnson, D. R., Raghupathy, R., and Strominger, J. L. Purification and characterization of class II histocompatibility antigens from homozygous human B cell line. J. Biol. Chem., 252: 16087-16094, 1987.
32. Marko, M. A., Chipperfield, R., and Birnboim, H. C. A procedure for the large-scale isolation of highly purified plasmid DNA using alkaline extraction and binding to glass powder. Anal. Biochem., 121: 382-387, 1982.
33. Orlandi, R., Gussow, D. H., Jones, P. T., and Winter, G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA, 86: 3833-3837, 1989.
34. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
35. Potter, H. Electroporation in biology: methods, applications, and instrumentation. Anal. Biochem., 174: 361-373, 1988.
36. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1997. CA Cancer J. Clin., 47: 5-27, 1997.
37. Goodwin, D. A. Tumor pretargeting: almost the bottom line. J. Nucl. Med., 36: 876-879, 1995.
38. Goodwin, D. A., and Meares, C. F. Pretargeting: general principles. October 10-12, 1996. Cancer (Phila.), 80: 2675-2680, 1997.
39. Saga, T., Weinstein, J. N., Jeong, J. M., Heya, T., Lee, J. T., Le, N., Paik, C. H., Sung, C., and Neumann, R. D. Two-step targeting of experimental lung metatases with biotinylated antibody and radiolabeled streptavidin. Cancer Res., 54: 2160-2165, 1994.
40. Sung, C., van Osdol, W. W., Saga, T., Neumann, R. D., Dedrick, R. L., and Weinstein, J. N. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res., 54: 2166-2175, 1994.
41. Khawli, L. A., Alauddin, M., and Miller, G. K. Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabeled streptavidin. Antibody Immunoconj. Radiopharmac., 6: 13-19, 1993.
42. Hnatowich, D. J., Virzi, F., and Rusckowski, M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med., 28: 1294-1302, 1987.
43. Stoldt, H. S., Aftab, F., Chinol, M., Paganelli, G., Luca, F., Testori, A., and Geraghty, J. G. Pretargeting strategies for radio-immunoguided tumour localisation and therapy. Eur. J. Cancer, 33: 186-192, 1997.
44. Kobayashi, H., Sakahara, H., Hosono, M., Yao, Z. S., Toyama, S., Endo, K., and Konishi, J. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a "chase" without decreased accumulation in the target tumor. J. Nucl. Med., 35: 1677-1684, 1994.
45. Paganelli, G., Chinol, M., Grana, C., Fiorenza, M., Cremonisi, R., and Franseschini, R. Therapy trials in cancer patients using an improved 3-step pretargeting approach. In: H. Bergman, H. Kroiss, and H. Sinzinger (eds.), Radioactive Isotopes in Clinical Medicine and Research, pp. 513-517. Boston: Birkhauser Verlag, 1997.
46. Paganelli, G., Magnani, P., Zito, F., Villa, E., Sudati, F., Lopalco, L., Rossetti, C., Malcovati, M., Chiolerio, F., and Seccamani, E. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res., 51: 5960-5966, 1991.
47. Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., and Weiner, L. M. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res., 58: 485-490, 1998.